BIO is committed to increased access to biologic medicines for patients throughout the world. 

The Patent Reform Act of 2011 would strengthen and improve our nation’s patent system, spurring innovation and job creation.

Position Title: Director, Policy Research and Analytics                        
Department: Policy Department
Reports to: Managing Director, Reimbursement and Health Policy

Primary Purpose of the Position:

Position Title: Director, Federal Government Relations                                        
Department:  Federal Government Relations
Reports to: SVP, Federal Government Relations

Primary Purpose of the Position:   Lead Democratic Senate lobbyist for the Federal Government Relations Department on health matters (aside from appropriations) and judiciary matters.

Position Title:     Director, Federal Government Relations                                        
Department:       Federal Government Relations
Reports to:          SVP, Federal Government Relations

Position Title: Director, Events Communications
Department: Communications
Reports to: Senior Vice President, Communications


Primary Purpose of the Position:


We offer a competitive benefits package. Send resume, cover letter, and salary requirements to:

Biotechnology Industry Organization
Human Resources Department
1201 Maryland Avenue, SW
Suite 900
Washington, DC 20024
Phone: 202.962.9200
Fax: 202.488.6308

Position Title: Manager, Online Services
Department: Business Strategy
Reports to: VP, Business Strategy


Primary Purpose of the Position:

At the tenth anniversary of the month that the Renewable Fuel Standard was signed into law, the program has displaced nearly 1.9 billion barrels of foreign oil and consequently saved 589.33 million metric tons of U.S. transportation-related carbon emissions. The reduction is equivalent to removing more than 124 million cars from the road over the decade.

Position Title: Managing Director, Communications

Department: Communications

Reports to: Senior Vice President of Communications

Primary Purpose of the Position:

Nearly 30 million Americans suffer from a rare disease or condition. Despite the large number of patients living with rare diseases, only four percent of rare diseases have an approved treatment. As such, many patients suffering from a rare disease lack any treatment options.

The Orphan Drug Act (ODA) is an issue of huge importance to the rare disease community, patients, and families. Its impact on their lives is beyond measure. The incentives the ODA established for rare disease drug development—including the Orphan Drug Tax Credit—have successfully spurred innovation in treatment options for rare diseases (i.e., those that impact fewer than 200,000 people in the U.S.). Since the ODA was enacted in 1983, the Food and Drug Administration (FDA) has approved 486 orphan products, granted 3,280 orphan drug designations, and received 4,378 orphan drug designation requests.1,2 Yet even these numbers do not reflect the full impact of the ODA on rare disease drug development since some of these innovative products have been approved for more than one disease or condition. For the rare disease community, these orphan products may not only significantly improve quality of life, but may be life-saving. The patient stories included below show the impact of orphan drugs on these individual patients, and serve as examples of the potential impact of orphan drugs on rare disease patients’ lives.

More than a decade ago, the NIH Roadmap and the FDA Critical Path Report brought significant public attention and new programmatic efforts to advance translational research as the bridge between the promise of bioscience discoveries and the advancement of new biomedical innovations to improve the lives of patients. Of particular importance for accelerating translational research and overcoming the challenging environment for bioscience innovation is advancing collaborations between industry and academia as a means to both improving R&D productivity and reducing the costs of translating discoveries into new medical products.

Entrepreneurial biotechnology companies are at the forefront of a revolution in our understanding of the genetic and biomolecular basis of disease. The future of medicine will harness 21st century scientific tools, advancements in molecular biology, and novel bioinformatics to develop and improve upon therapies that can prevent, diagnose, and treat all stages of disease. Forward-looking public policies that sustain scientific discovery and promote biomedical advancement will help save lives and reduce and eliminate suffering.

Page is under construction.

This White Paper was developed by the Structured Benefit-Risk Working Group of the Biotechnology Industry Organization (BIO). The paper identifies considerations for biopharmaceutical companies who choose to use FDA’s Structured Benefit-Risk Assessment Framework earlier and more broadly throughout a product’s lifecycle as a mechanism to both solicit patient perspectives on areas of unmet medical need and assess patient preferences, and to align with FDA on key benefit-risk considerations.


BIO Industry Analysis team released a new report, Emerging Therapeutic Company Investment and Deal Trends, to look at five key investment and deal-making activities made exclusively by emerging therapeutic companies: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions.


  North Carolina   Senator Burr R & Senator Tillis R

EPA’s delays in RFS rulemaking over the past two years have chilled necessary investment in advanced and cellulosic biofuels just as they reached commercial deployment. We estimate the industry has experienced a $13.7 billion shortfall in investment as a result.

BIO member companies are committed to making innovative biotechnology medicines available to patients who need them through efficient development of approved, safe and effective products.

Thank you for your interest in joining the Biotechnology Industry Organization (BIO). Your application has been successfully submitted. It can take up to 3 business days to verify eligibility and correct selection of the membership category. Payment information will be included in the approval notification.

If you have any questions in the meantime, please contact Rosemary Garcia, Membership Customer Service, at, 202-962-9208.

Thank you, your submission has been received.